Somaxon's Silenor Could Switch OTC In Five To Seven Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite a "clear path" from FDA for the insomnia drug, the firm will need to conduct efficacy, safety and label comprehension studies, and may use a lower-than-Rx dose.
You may also be interested in...
Silenor Deal Gives P&G Easy Access To Rx Market, Possible OTC Sales
Procter & Gamble's license to market the insomnia drug Silenor lets the firm re-enter the Rx drug market without development costs and opens the door to a potential OTC switch
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.